Study of A-301 in patients with patchy alopecia areata
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs ATI 50002 (Primary)
- Indications Alopecia areata
- Focus Adverse reactions
- Sponsors Aclaris Therapeutics
- 08 Aug 2017 According to an Aclaris Therapeutics media release, the company has submitted an IND Application to the U.S. FDA. Following FDA clearance of the IND, the company expects to initiate this trial in the second half of 2017.
- 29 Mar 2016 New trial record
- 23 Mar 2016 According to Aclaris Therapeutics media release, company plans to submit IND in in the first half of 2017 and plans to commence this study in the first half of 2017.